Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.99 USD | +3.48% | +18.43% | 0.00% |
Apr. 22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
Apr. 22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
Evolution of the average Target Price on Boundless Bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Boundless Bio, Inc.
Piper Sandler | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- BOLD Stock
- Consensus Boundless Bio, Inc.